The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 89 (high attention) · dilution pressure high · listing risk high · governance risk low · runway 1.1 mo · strongest signal: Exchange deficiency notice (Aug 3, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (atm program, pipe, registered direct). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 108 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 3, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-08-03 (accepted 16:30 ET) filing | 55 |
| Aug 3, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-08-03 filing | 46 |
| Aug 3, 2026 | ▼ ATM program | “atm” language in 8-K (EX-10.1) filed 2026-08-03 filing | 44 |
| Aug 3, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-03 (accepted 16:30 ET) filing | 34 |
| Aug 3, 2026 | ▼ Registered direct | “rdo” language in 8-K (EX-10.1) filed 2026-08-03 filing | 34 |
| Aug 3, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-3.1) filed 2026-08-03 filing | 33 |
| Jul 22, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-K (10-K) filed 2026-07-22 filing | 25 |
| Apr 30, 2026 | ▼ Runway < 6 months | ~1.1 months runway: liquidity $710,689 as of 2026-04-30, burn $8,067,813/yr (latest fiscal-year operating cash flow [companyfacts]) filing | 43 |
| Apr 30, 2026 | ▼ Share count +25% | Shares outstanding 3,804,741 (2026-03-11) -> 4,791,525 (2026-07-22), +26% filing | 33 |
| Apr 30, 2026 | ▼ Cash < current liabilities | Liquidity $710,689 vs current liabilities $3,826,457 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →